Michael J. Droller, M.D., is a board certified urologist who received his medical degree cum laude from Harvard Medical School. He completed his internship in internal medicine at the Albert Einstein College of Medicine, went on to begin a surgical residency at the Peter Bent Brigham Hospital in Boston, and then took a position in the US Public Health Service at the National Institutes of Health as a Clinical Associate in the National Institute of Arthritis and Metabolic Diseases to pursue clinical and laboratory investigations. He completed his urology residency at Stanford University Medical Center, spent a year in immunologic research in the Department of Immunology at the University of Stockholm, and then joined the faculty in the Departments of Urology and Oncology at the Johns Hopkins Hospital and School of Medicine. Dr. Droller came to Mount Sinai as Professor and Chairman of the Department of Urology in 1984, serving in that capacity for 19 years and becoming the Katherine and Clifford Goldsmith Professor of Urology (1998) and Professor of Oncology.
Dr. Droller's clinical interests center on urological cancers, with a major focus on bladder cancer and prostate cancer. In pursuing these areas both clincally and in the laboratory, he has also been extensively involved in teaching and communicating to professional colleagues and to the public on these topics, through serving in several major leadership positions for a number of major organizations and professional journals. He founded the Prostate Health Center for the Department in 1999. He is currently Editor-in-Chief of Urologic Oncology: Seminars and Original Investigations, which is the official journal of the Society of Urologic Oncology. He is also Associate Editor of the Journal of Urology, the official journal of the American Urological Association. He has also served as Chairman of the Medical Advisory Council for the American Foundation for Urological Diseases, having served as co-Chair for the Bladder Health Council of that organization for 12 years. He has been President and on the Executive Committee of the Society of Urologic Oncology, the Urological Research Society, the New York Section of the American Urological Association, and the New York State Urological Society, and has served as Chairman of the Section of Urology of the New York Academy of Medicine. In addition, he is a member of 15 professional societies and on the editorial board of eight professional journals. His government service has included terms as consultant to the Island Peer Review Organization on the Standards Norms and Criteria Committee and the New York State Department of Health Task Force on Clinical Guidelines and Medical Terminology Assessment.
American Board of Urology
MD, Harvard Medical School
Internship, Internal Medicine
Albert Einstein College of Medicine
Brigham and Women's Hospital
Stanford University Hospital
English, German, Spanish
Legends in Urology
Canadian Journal of Urology
Swedish Urologic Association
Career Achievement Award
Societe Internationale d'Urologie
International Bladder Cancer Network
Doctor of Medicine Honoris Causa
University of Athens
German Urological Association
New York Magazine/Castle Connolly
Alpha Omega Alpha
Medical Honor Society, Harvard Medical School
Phi Beta Kappa
Sigma Xi Research Honor Society
Droller MJ. Advanced Bladder Cancer. Philadelphia, Pennsylvania, Urologic Clinics N. America, W.B.Saunders; 1992.
Zietman A, Smith J, Klein E, Droller M, Dasgupta P, Catto J. Describing the Grade of Prostate Cancer: Consistent Use of Contemporary Terminology Is Now Required. European urology 2016 Jul; 70(1).
Smith JA, Zietman A, Klein E, Droller MJ, Dasgupta P, Catto J, Smith JA. Stage Grouping. The Journal of urology 2016 Jun; 195(6).
Zietman A, Smith J, Klein E, Droller M, Dasgupta P, Catto J. Consensus guidelines for reporting prostate cancer Gleason Grade. BJU international 2016 Jun; 117(6).
Grossman HB, Gomella L, Fradet Y, Droller MJ, Presti J, Ritenovr C, Nseyo U, Morales A. A phase III multicenter comparison of hexaminolevulinate (HAL) flourescence cystoscopy and white light cystoscopy for the detection of superficial papillary lesions in patients with bladder cancer. J. Urol. 2007; 178: 622-667.
Zietman A, Smith J, Klein E, Droller M, Dasgupta P, Catto J. Consensus Guidelines for Reporting Prostate Cancer Gleason Grade. Urology 2016 Jul; 93.
Droller MJ. Urothelial Tumors. Hamilton Canada, BC Decker, Inc; 2004.
Droller MJ. Current concepts of tumor markers in bladder cancer. Urologic Clinics N America 2002 Feb; 29(1): 229-234.
Droller MJ. Bladder Cancer: Current Diagnosis and Treatment. Totowa, New Jersey, Humana Press; 2001.
Droller MJ, Malmstrom PU. Premalignant lesions and carcinoma in situ in bladder neoplasia: introduction and overview. Scand J Urol Nephrol 2000; Suppl 205: 62-66.
Landman J, Chang Y, Kavaler E, Droller MJ, Liu BC S. Sensitivity and specificity of NMP-22, telomerase, and BTA in the detection of human bladder cancer. Urology 1998 Sep; 52(3): 398-402.
Kavaler E, Landman J, Chang Y, Droller MJ, Liu BC. Detecting human bladder carcinoma cells in voided urine samples. Cancer 1998 Feb 15; 82(4): 708-714.
Shemtov MM, Chang DL C, Kong L, Shu WP, Sassaroli M, Droller MJ, Liu BC S. LAK cell mediated apoptosis of human bladder cancer cells involves a pH-dependent endonuclease system in the cancer cell: Possible mechanism of BCG therapy. J Urol 1995; 154: 269-271.
Jones PA, Droller MJ. Pathways of development and progression in bladder cancer: New correlations between clinical observations and molecular mechanisms. Semin Urol 1993 Nov; 11(4): 177-192.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Droller during 2015 and/or 2016. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.